- Roche's (OTCQX:RHHBY) Genentech unit is suing Amgen (AMGN -0.5%) in the U.S. for access to manufacturing information it calls "highly relevant" to determine if Amgen's biosimilar to Avastin (bevacizumab) infringes on its patents. It wants the court to intervene before Amgen's product is approved by the FDA so it has "sufficient time" to assert its patents. The complaint accuses Amgen of obstructing its ability to conduct its analysis.
- If Genentech fails to list a particular patent, it could be permanently barred from asserting it, according to the filing. It adds that it could lose certain rights as soon as March 24.
- Amgen's U.S. marketing application was filed with the FDA in mid-November 2016.
- Source: Bloomberg